Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Metis TechBio Co., Ltd.
劑泰科技(北京)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 7666)

INSIDE INFORMATION
PROPOSED A SHARE LISTING PLAN

This announcement is made by Metis TechBio Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**" or "**Metis TechBio**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**") and the inside information provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of the Company is pleased to announce that, in order to facilitate business development and enhance the overall competitive strength of the Company, the Company intends to commence work relating to the issuance of RMB-denominated ordinary shares (the "**A Shares**") and listing of such shares (the "**Proposed A Share Listing**"). The Board has resolved and approved the commencement of the relevant work in relation to the Proposed A Share Listing.

In connection with the Proposed A Share Listing, the Company has engaged a pre-listing tutoring institution, and will submit a tutoring filing application for the Proposed A Share Listing to the relevant regulatory authorities in accordance with applicable laws and regulations. As at the date of this announcement, the Board has not approved any other plans relating to the Proposed A Share Listing, nor has it applied to any relevant regulatory authority in the PRC for approval of the Proposed A Share Listing.

Shareholders and potential investors of the Company are reminded that any detailed plans and expected timetable for the Proposed A Share Listing are subject to further approval by the Board and the general meeting of the Company, as well as the consent of the China Securities Regulatory Commission and other relevant regulatory authorities. Accordingly, the Proposed A Share Listing may or may not proceed. Shareholders and potential investors of the Company are advised that there is no assurance that the Proposed A Share Listing will take place or when it will take place. The Company will make further filings and announcements in relation to the Proposed A Share Listing in due course in accordance with the requirements of the Listing Rules and other applicable laws and regulations. This announcement is for reference only and is not intended to constitute an invitation, offer or any part thereof to acquire, purchase or subscribe for the shares of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company, and should consult their professional advisers if they have any doubts about the Company's situation or the action to be taken.

ABOUT METIS TECHBIO

Metis TechBio was co-founded in 2020 by Dr. Hongming Chen, a member of the U.S. National Academy of Engineering, along with MIT scientists Dr. Tsai-Ta Lai and Dr. Wenshou Wang. The Company was successfully listed on the Hong Kong Stock Exchange on May 13, 2026 as the "world's first listed company of AI drug delivery". The Company has independently developed NanoForge, the world's first AI-driven nano-delivery platform, and owns the world's largest proprietary LNP lipid library with over 10 million lipids. Based on NanoForge, the Company has built four core solutions: AiLNP (AI nano-delivery system design platform), AiRNA (AI mRNA sequence design platform), AiProtein (AI protein design platform), and AiTEM (AI small molecule formulation design platform).

The Company has achieved the capability for precise and targeted delivery to eight key organs or tissues, including the liver, lungs, muscles and immune cells, and has made breakthrough progress in addressing the challenge of multi-organ and multi-tissue targeted delivery, providing druggability opportunities for oncology, metabolic diseases, autoimmune diseases and neurodegenerative diseases, while also offering the potential for anti-aging at the organ level.

By Order of the Board
Metis TechBio Co., Ltd.
Tsai-Ta Lai
Chairman of the Board, executive Director and chief executive officer

Hong Kong, November 18, 2026

As of the date of this announcement, the Board comprises Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as independent non-executive Directors.